New Virus Identified in Blood Supply
|
By LabMedica International staff writers Posted on 30 Sep 2015 |
|
Image: The HiSeq 2500 sequencing platform (Photo courtesy of Illumina).
Transfusion of blood or blood-derived products can save lives and improve health but requires safety measures for preventing bystander transmission of infectious agents.
To investigate the transmission of novel infectious agents by blood transfusion, changes in the virome composition of blood transfusion recipients pre- and post-transfusion has been studied.
An international group of scientists led by those at Columbia University (New York, NY, USA) collected serum samples from four participating blood centers distributed across the USA from July 1974 through June 1980. They performed high-throughput sequencing on blood samples from 46 individuals in the in the Transfusion-Transmitted Viruses Study (TTVS). They also performed high-throughput sequencing on samples from 106 individuals in the Multicenter Hemophilia Cohort Study who received plasma-derived clotting factor concentrates.
Total ribonucleic acid (RNA) extracts were reverse transcribed using a SuperScript III kit (Invitrogen Life Technologies; Carlsbad, CA, USA) with random hexamer primers. After processing, samples with low concentrations were amplified by increasing polymerase chain reaction (PCR) cycle numbers from 9 to 14. All sequencing was done on the Illumina HiSeq 2500 platform (Illumina; San Diego, CA, USA), yielding an average of 150 million reads per sequencing lane.
The team analyzed samples both pre- and post-transfusion and along with a variety of known viruses, they identified a new virus in two individuals. The virus was only present in post-transfusion samples, and additional tests showed that both patients were able to clear the virus. Genetic analysis determined that the novel human virus, human hepegivirus 1 (HHpgV-1) was related to Hepatitis C virus (HCV) and human Pegivirus (HPgV; formerly called GB virus C or Hepatitis G virus). Genomic testing of 70 additional individuals in the TTVS study failed to detect further cases of the virus detected. HHpgV-1 was found in serum samples from two blood transfusion recipients and two hemophilia patients who had received plasma-derived clotting factor concentrates.
Amit Kapoor, PhD, an assistant professor and lead author of the study said, “HHpgV-1 is unique because it shares genetic similarity with both highly pathogenic HCV and the apparently non-pathogenic HPgV. People need to be aware of this new infection in humans. We just don't know how many viruses are transmitted through the blood supply. There are so many viruses out there, and they need to be characterized in order to ensure that transfusions are safe.” The study was published on September 22, 2015, in the journal mBio.
Related Links:
Columbia University
Invitrogen Life Technologies
Illumina
To investigate the transmission of novel infectious agents by blood transfusion, changes in the virome composition of blood transfusion recipients pre- and post-transfusion has been studied.
An international group of scientists led by those at Columbia University (New York, NY, USA) collected serum samples from four participating blood centers distributed across the USA from July 1974 through June 1980. They performed high-throughput sequencing on blood samples from 46 individuals in the in the Transfusion-Transmitted Viruses Study (TTVS). They also performed high-throughput sequencing on samples from 106 individuals in the Multicenter Hemophilia Cohort Study who received plasma-derived clotting factor concentrates.
Total ribonucleic acid (RNA) extracts were reverse transcribed using a SuperScript III kit (Invitrogen Life Technologies; Carlsbad, CA, USA) with random hexamer primers. After processing, samples with low concentrations were amplified by increasing polymerase chain reaction (PCR) cycle numbers from 9 to 14. All sequencing was done on the Illumina HiSeq 2500 platform (Illumina; San Diego, CA, USA), yielding an average of 150 million reads per sequencing lane.
The team analyzed samples both pre- and post-transfusion and along with a variety of known viruses, they identified a new virus in two individuals. The virus was only present in post-transfusion samples, and additional tests showed that both patients were able to clear the virus. Genetic analysis determined that the novel human virus, human hepegivirus 1 (HHpgV-1) was related to Hepatitis C virus (HCV) and human Pegivirus (HPgV; formerly called GB virus C or Hepatitis G virus). Genomic testing of 70 additional individuals in the TTVS study failed to detect further cases of the virus detected. HHpgV-1 was found in serum samples from two blood transfusion recipients and two hemophilia patients who had received plasma-derived clotting factor concentrates.
Amit Kapoor, PhD, an assistant professor and lead author of the study said, “HHpgV-1 is unique because it shares genetic similarity with both highly pathogenic HCV and the apparently non-pathogenic HPgV. People need to be aware of this new infection in humans. We just don't know how many viruses are transmitted through the blood supply. There are so many viruses out there, and they need to be characterized in order to ensure that transfusions are safe.” The study was published on September 22, 2015, in the journal mBio.
Related Links:
Columbia University
Invitrogen Life Technologies
Illumina
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
HPV Test
Allplex HPV28 Detection
Prefilled Tubes
Prefilled 5.0ml Tubes
Latest Molecular Diagnostics News
- Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer
- Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation
- Machine Learning Approach Expands Epigenetic Testing for Prenatal Genetic Disorders
- New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples
- Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth
- Liquid Biopsy Combines Multiple Signals for Cancer Detection in a Single Analysis
- Newborn Screening Program Adds Spinal Muscular Atrophy Testing Across England
- Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings
- Liquid Biopsy Assay Enriches Tumor DNA for Early Detection and Monitoring
- Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy
- Point-of-Care Multiplex PCR Test Submitted to FDA for Flu A/B and RSV Detection
- New PCR Assays Expand Cyclospora Testing for Outbreak Surveillance
- Single Liquid Biopsy Predicts Early Immunotherapy Benefit in Advanced Lung Cancer
- Machine Learning Tool Improves Prediction of Liver Cancer Recurrence
- AI-Powered Liquid Biopsy Detects Liver Cancer Across Diverse Populations
- Circular RNAs Enable Noninvasive Cancer Detection and Risk Assessment
Channels
Clinical Chemistry
view channel
Rapid Breath Sensor Detects SARS-CoV-2 from Exhaled Air
Nasal swabs and polymerase chain reaction (PCR) testing have been central to identifying SARS-CoV-2, but they can be uncomfortable, slow, and logistically complex when samples require transport.... Read more
Head-to-Head Study Compares Blood Tests for Early Alzheimer’s Disease Detection
Accurate, scalable diagnostics are becoming increasingly important as disease-modifying therapies reshape Alzheimer’s disease care, yet many patients still rely on invasive cerebrospinal fluid sampling... Read more
Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy
Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more
Molecular Diagnostics
view channel
Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer
Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read more
Machine Learning Approach Expands Epigenetic Testing for Prenatal Genetic Disorders
Prenatal genetic testing is increasingly used to identify potential neurodevelopmental conditions, but results often include variants of uncertain significance that clinicians cannot confidently classify.... Read more
New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples
Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation
Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read more
Immunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read more
Pathology
view channel
AI Uses H&E Slides to Predict Key Biomarkers Across 32 Cancers
Molecular profiling is essential for characterizing solid tumors, but many laboratories still rely on separate genetic assays to detect alterations such as TP53 mutations. These workflows can be resource-intensive... Read more
AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
Pathology laboratories face growing case volumes, staffing pressures, and increasing diagnostic complexity that can delay results. At the same time, whole-slide images may contain quality defects such... Read more
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Technology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Strategic Collaboration Expands Commercial Access to Oncology Companion Diagnostics
CellCarta, a global CRO laboratory serving the biopharmaceutical industry, has announced a strategic collaboration with Tempus AI to broaden access to companion diagnostics (CDx) in oncology.... Read more
